3rd Quarter - Report

THE GIBSON GROUP, LLC for ENDO PHARMACEUTICALS INC.

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues relating to incentives for life sciences research. H.R. 523/S. 232: Protect Medical Innovation Act of 2013.

LobbyistCovered position, as disclosed
JOSEPH H GIBSON —

Contacted: HOUSE OF REPRESENTATIVES

Bills named: S. 232 (113th), H.R. 523 (113th)

Copyright/Patent/Trademark CPT

Oversight of implementation of the America Invents Act. Issues relating to patent settlements, including S. 214: Preserve Access to Affordable Generics Act. H.R. 3309: Innovation Act. S. 1720: Patent Transparency and Improvements Act of 2013.

LobbyistCovered position, as disclosed
JOSEPH H GIBSON —

Contacted: HOUSE OF REPRESENTATIVES

Bills named: S. 214 (113th), H.R. 3309 (113th), S. 1720 (113th)

Health Issues HCR

Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates. Issues relating to health information technology. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. Compounding and drug supply chain legislation. H.R. 3204: Drug Quality and Security Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs.

LobbyistCovered position, as disclosed
JOSEPH H GIBSON Counsel, House Judiciary Comm. '95-'97

Contacted: HOUSE OF REPRESENTATIVES

Bills named: H.R. 486 (113th), H.R. 3204 (113th), H.R. 1919 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.